Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting.
Journal
Ophthalmic research
ISSN: 1423-0259
Titre abrégé: Ophthalmic Res
Pays: Switzerland
ID NLM: 0267442
Informations de publication
Date de publication:
31 Mar 2022
31 Mar 2022
Historique:
received:
01
10
2021
accepted:
22
03
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
aheadofprint
Résumé
Uveal Melanoma (UM) is the most common primary intra-ocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "Outcome Measures of New Technologies in Uveal Melanoma", addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient's wellbeing. This review highlights the meeting's presentations in the context of the published literature.
Identifiants
pubmed: 35358966
pii: 000524372
doi: 10.1159/000524372
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
The Author(s). Published by S. Karger AG, Basel.